What's happening in and around the Park? Here's an update from the team at the Illinois Science + Technology Park. | |
Endeavor Health: Leadership Appointments | |
|
Endeavor Health has appointed Joe Dant and Sean O’Grady to newly created executive leadership roles designed to support the organization’s continued growth and operational excellence as one system.
Joe Dant, who most recently served as President, South Region and Institutes, including Edward, Elmhurst and Linden Oaks Hospitals, has assumed the new role of Endeavor Health’s System Chief Growth Officer.
Sean O’Grady has assumed the new role of President, Acute and Ambulatory Operations for the health system. O’Grady was most recently President, North Region and Institutes, including Evanston, Highland Park, Glenbrook, Northwest Community, Skokie and Swedish Hospitals.
Dant and O’Grady each bring more than 30 years of healthcare leadership experience to their new roles, including extensive expertise in strategy, operations and building high-performing, collaborative teams.
For more on this announcement, click here
.
| |
“This evolution in our organizational structure will provide clarity, focus and strengthen our path forward together,” said J.P. Gallagher, Endeavor Health President and CEO. “By harnessing the talents of two of our most experienced operations leaders in Joe and Sean, we will accelerate our progress in delivering on our mission and vision as a leading community-connected health system, bringing the best of what our health system has to offer to our patients, team members and communities.” | |
LanzaTech & Eramet: First-of-a-Kind Project | |
|
LanzaTech Global, Inc. the carbon recycling company transforming above-ground carbon into sustainable fuels, chemicals, materials, and proteins, announced plans to develop a commercial-scale Carbon Capture and Utilization facility at Herøya Industrial Park in Porsgrunn, Norway. The plant will produce ethanol and is expected to begin operations in 2028. Eramet will supply furnace gas as feedstock to the facility from the Porsgrunn Manganese Alloys smelter but will not participate in its financing.
To unlock further emissions reductions, the two companies also intend to build upon the CCU infrastructure and, if demonstrated to be feasible, integrate Carbon Capture and Storage (“CCS”) technology as part of a second phase of the project. The integration of LanzaTech’s CCU technology with CCS, two commercially proven carbon management solutions, is expected to establish a first-of-a-kind, integrated facility that drives leading-edge carbon abatement metrics.
The new plant at Herøya will complement the six other commercial scale plants already using LanzaTech’s carbon recycling technology to produce ethanol and the first for which LanzaTech will manage the full scope of project design, construction, and operations.
For more information, click here.
| |
“We are thrilled to announce plans for Norway’s first commercial carbon recycling facility using LanzaTech’s technology,” said Dr. Jennifer Holmgren, CEO of LanzaTech. “Carbon is an incredibly important resource that requires a wide range of solutions to manage responsibly. By recycling above-ground carbon with our CCU process, this groundbreaking project gets us another step closer to realizing an enduring global circular carbon economy.” | |
Renovation & Updates at 8045 Lamon | |
|
The transformation of the ISTP campus draws inspiration from the fusion of science and nature, reinforcing the campus's commitment to wellness and sustainability. Updated common areas are designed to promote physical activity, social interaction, collaboration and a sense of connection in a dynamic scientific setting, marking a new chapter in the campus’s evolution.
The dramatic four-story atrium at the heart of the campus is anchored by a vertical volume of stacked meeting spaces clad in wood slats. Thoughtful lighting upgrades help define the architectural volume, while moveable furniture allows the large space to seamlessly transition from a third workplace to hosting informal gatherings and community events.
Hospitality-inspired areas for relaxation provide a comforting escape from structured lab environments. The redesign also extends to the auditorium and conference center, equipped with new technology, while refreshed locker rooms and restrooms feature spa-like amenities to further enrich the user experience.
Sustainability is a key focus of the design, with recycled content and carbon-neutral products prioritized in material selection. Biophilia-themed furnishings and finishes, along with carefully selected art pieces throughout the campus support the concept of scientific journey.
| |
|
Choosing the Right CDMO Partner is Key | |
|
Vetter provides comprehensive resources for early phase clinical manufacturing.
API protection
Your valuable drug substance is handled with regulatory and quality safeguards at every step.
Customized outputs
Tailored clinical production to your needs, from a few hundred Phase 1 units to large Phase 3 batches.
Accelerated time-to-market
Services that can help expedite your product’s path to market – and to patients who need your clinical breakthrough.
Experience with complex molecules
Supporting a wide range of substance classes, including oligonucelotides, monoclonal antibodies, fusion proteins, peptide hormones, and coagulation factors.
| |
|
Vetter is a trusted source for clinical supplies.
With Vetter as your partner, skilled project managers will guide you through key fill-and-finish processes across your product’s development cycle. To learn more, click here.
| |
Westfield Old Orchard Redevelopment Plans | |
|
The Skokie Village Board advanced plans for the two-phase redevelopment of Westfield Old Orchard shopping center.
Plans will bring residential use to the property and enhance retail, dining, shopping and entertainment experiences:
Phase 1 would demolish the former Bloomingdale’s space at the northwest portion of the mall and construct a five-story and a seven-story mixed-use building with more than 400 residential apartments, 16,000 square feet of restaurant and retail space, and a new public common area and event space.
Phase 2 would include demolition of the existing retail space at the north end of the shopping center and construction of a 7-story mixed-use building that will contain retail and restaurant uses, 250 residential units, residential amenity space, and a parking garage; along with an 8-story mixed-use building that will contain retail and restaurant uses and a 200-key hotel or up to 125 residential units.
Click for more information.
| |
“Westfield Old Orchard already provides an exceptional experience for our customers, residents, and our office workers. Our bold new vision for the center will dramatically enhance its offering and further establish it as the preeminent live, work, shop, and play destination on the North Shore. By creatively unlocking the potential of the center, this development will bring new life, energy and choices to Old Orchard and create what will become the residential, commercial, and cultural heart of Skokie.” noted Maegen Akers, General Manager, Westfield Old Orchard. | |
COUR Pharmaceuticals Announces Positive Top-line Results | |
|
COUR Pharmaceuticals, a clinical-stage biotechnology company developing first-in-class, disease-modifying therapies designed to induce antigen-specific tolerance for immune-mediated diseases, announced positive 120-day data from its Phase 2a study evaluating CNP-104 as a potential treatment for patients with Primary Biliary Cholangitis (PBC), a chronic liver disease that is estimated to affect approximately 130,000 individuals in the U.S.
The Phase 2a first-in-human, proof-of-concept, randomized clinical trial (NCT05104853) is designed to assess the safety, tolerability, pharmacodynamics, and efficacy of CNP-104 in patients aged 18-75, unresponsive to treatment with ursodeoxycholic acid (UDCA) and/or obeticholic acid (OCA).
Participants received 4 mg/kg or 8 mg/kg of CNP-104 or placebo on Days 1 and 8 with all patients receiving two I.V. loading doses administered one week apart. Of the 41 subjects dosed, the final randomization ratio approximated 1:1:1 placebo to 4 mg/kg CNP-104 to 8 mg/kg CNP-104. This study report considers the 120-day primary study period while the 20-month long-term safety evaluation is ongoing.
| |
|
“These data highlight the potential of CNP-104 to be the first disease-modifying treatment for people living with PBC,” said Paul M. Peloso, M.D., Chief Medical Officer of COUR Pharmaceuticals.
“In addition to safety and tolerability data supporting further studies, we observed multiple immunological and clinical measurements supporting mechanistic proof of concept for CNP-104. Additionally, we observed positive clinical endpoints such as a reduction in liver stiffness measured on Fibroscan in the active arms compared to placebo, with Fibroscan being a surrogate for reductions in fibrosis. These data suggest that CNP-104 has the potential to halt disease progression which would be a transformational advancement for people living with PBC. We look forward to presenting these encouraging data at an upcoming scientific meeting.” added Peloso.
To read the entire press release, click here.
| |
Illinois: King of Midwest Commerce | |
|
The evidence that Illinois is a top-performing business environment keeps writing itself. In March, Site Selection magazine reported that Illinois ranked second in the nation for corporate expansions and relocations for the second straight year. Illinois tallied 552 corporate facility projects in 2023, up from 487 in 2022.
Greater Chicago ranked as the No. 1 top-performing metro area in the country for a record-setting 11th year in a row.
There are 500,000 college students within three hours of Chicago. Many of them attend colleges or universities ranked among the world’s best. For example, the University of Chicago ranks as the No. 6 Best College for Public Policy in America, per niche.com. It ranks in the top 10 in nine other categories. According to U.S. News & World Report, the University of Illinois Urbana-Champaign ranks as the No. 12 best public university in America and 35th best overall. It ranks in the top 10 nationally in library and information science; accounting; civil engineering, materials engineering; and general engineering.
| |
|
“Illinois continues to attract leading companies to our state, with hundreds of openings and expansions every year,” said Gov. JB Pritzker.
“With our unique incentives, our growing market, and our diverse and talented workforce, there’s no doubt that the economy in Illinois is thriving. This impressive recognition from Site Selection Magazine for the second year in a row makes it clear: Illinois is back and open for business.”
To learn more about Illinois as a location for your business, click here.
| |
CASMI Wins 2024 Chicago Innovation Award | |
|
UL Research Institutes–Northwestern University partnership recognized for advancing AI safety.
The Center for Advancing Safety of Machine Intelligence (CASMI) research hub, a partnership between UL Research Institutes and Northwestern University, has won a Chicago Innovation Award for its work to better incorporate safety into artificial intelligence.
The Materials Discovery Research Institute’s (MDRI) artificial intelligence-powered strategies for creating new materials to tackle climate change-related challenges are featured in a recent Chicago Tribune story.
Highlighting the institute’s goals to create new materials that will produce clean energy, water, and air, the Nov. 7 news story reports on the MDRI lab’s state-of-the-art equipment and automated processes. The story also covers how MDRI’s innovative lab aims to accelerate groundbreaking discovery.
CASMI has collaborated with ULRI’s Digital Safety Research Institute (DSRI) since February 2022 to establish a wide-ranging research network focused on creating the knowledge to develop artificial intelligence (AI) systems for safe and equitable use. As part of its mission, CASMI funds selected research projects across about 10 universities that focus on key AI challenges.
To read the entire announcement, click here..
| |
G.D. Searle: North Shore Chicago Legacy | |
|
The Illinois Science + Technology Park started with the former corporate headquarters of pharmaceutical giant G.D. Searle and has created a community of scientists, inventors, and innovators. We are dedicated to the cultivation of a multi-cultural environment that will create and sustain businesses from basic research through commercialization. This environment includes world class laboratories, office space and key support amenities.
Why Skokie? The company was located in the Ravenswood area of Chicago. The management was looking for a campus like setting where it could grow through out the second half of the 20th century. The decision to establish its operations in Skokie was driven by various strategic factors, including the area's favorable business environment, proximity to key markets, and access to skilled talent pool. This move not only enhanced the company's operational efficiency but also solidifies its position as a key player in the pharmaceutical industry. Learn more about ISTP.
| |
Honoring Chad Mirkin @IIN at Northwestern | |
Illinois: Advancing Innovation | | | | |